Evidence map›Paper›PMID 36294555›Full record

ArticleJournal of fungi (Basel, Switzerland)2022

Reactivation of Coccidioidomycosis in a Mouse Model of Asymptomatic Controlled Disease.

Lisa F Shubitz, Daniel A Powell, Sharon M Dial, Christine D Butkiewicz, Hien T Trinh, Amy P Hsu, Adam Buntzman, Jeffrey A Frelinger, John N Galgiani

Open access · goldAbstract read
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. From soil to clinic: current advances in understandingMicrobiology and molecular biology reviews : MMBR · 2024
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Lisa F ShubitzValley Fever Center for Excellence, University of Arizona, 1656 E Mabel St., Tucson, AZ 85719, USA.
Daniel A PowellValley Fever Center for Excellence, University of Arizona, 1656 E Mabel St., Tucson, AZ 85719, USA.
Sharon M DialCollege of Veterinary Medicine, University of Arizona, 1580 E Hanley Blvd, Oro Valley, AZ 85737, USA.
Christine D ButkiewiczValley Fever Center for Excellence, University of Arizona, 1656 E Mabel St., Tucson, AZ 85719, USA.
Hien T TrinhValley Fever Center for Excellence, University of Arizona, 1656 E Mabel St., Tucson, AZ 85719, USA.
Amy P HsuLaboratory of Clinical Immunology and Microbiology, NIAID, Building 10, 10 Center Drive, Bethesda, MD 20892, USA.ORCID 0000-0001-6841-2122
Adam BuntzmanValley Fever Center for Excellence, University of Arizona, 1656 E Mabel St., Tucson, AZ 85719, USA.ORCID 0000-0003-1067-4618
Jeffrey A FrelingerValley Fever Center for Excellence, University of Arizona, 1656 E Mabel St., Tucson, AZ 85719, USA.
John N GalgianiValley Fever Center for Excellence, University of Arizona, 1656 E Mabel St., Tucson, AZ 85719, USA.ORCID 0000-0002-7882-1883
University of Arizona · US

Funding

An Avirulent Arthroconidial Vaccine Candidate to Prevent Human CoccidioidomycosisR01AI132140 · NIAID · UNIVERSITY OF ARIZONA · PI GALGIANI, JOHN N · 2017 to 2020
$4.8M
National Institute of Allergy and Infectious Diseases RO1-AI-132140National Institute of Allergy and Infectious Diseases UO1-AI-122275NIAID NIH HHS R01 AI132140
6 · The paper itself

Abstract

The majority of human coccidioidomycosis infections are asymptomatic or self-limited but may have sequestered spherules in highly structured granulomas. Under immunosuppression, reactivation of fungal growth can result in severe disease. B6D2F1 mice asymptomatically infected with C. posadasii strain 1038 were immunosuppressed with dexamethasone (DXM) in drinking water. Treated mice died 16−25 days later, while untreated mice survived (p < 0.001). Flow cytometry of lung granulomas on days 5, 10, 15, and 20 of DXM treatment showed immune cell populations decreased 0.5−1 log compared with untreated mice though neutrophils and CD19+IgD−IgM− cells rebounded by day 20. Histopathology demonstrated loss of granuloma structure by day 5 and increasing spherules through day 20. On day 20, T-cells were nearly absent and disorganized pyogranulomatous lesions included sheets of plasma cells and innumerable spherules. Mice given DXM for 14 days then stopped (DXM stop) survived 6 weeks (9/10). Lung fungal burdens were significantly lower (p = 0.0447) than mice that continued treatment (DXM cont) but higher than untreated mice. Histopathologically, DXM stop mice did not redevelop controlled granulomas by sacrifice, though T-cells were densely scattered throughout the lesions. This demonstrates a mouse model suitable for further study to understand the immunologic components responsible for maintenance control of coccidioidomycosis.

Indexed as

Coccidioidesgranulomaimmunosuppressionmicereactivation

Identifiers

PMID36294555
PMCPMC9605249
OpenAlexW4296629901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.